Trevi Therapeutics Initiated at Buy by Rodman & Renshaw

Trevi Therapeutics Initiated at Buy by Rodman & Renshaw

Dow JonesJun 13 13:50 ET

Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.

BenzingaJun 13 13:40 ET

Rodman & Renshaw Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $7

Rodman & Renshaw analyst Elemer Piros initiates coverage on $Trevi Therapeutics(TRVI.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate

moomoo NewsJun 12 18:32 ET · Ratings

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:

BenzingaJun 6 16:31 ET

Form 144 | Trevi Therapeutics(TRVI.US) Officer Proposes to Sell 136.62K in Common Stocks

SEC FILLINGS DISCLOSED/ May 29, $Trevi Therapeutics(TRVI.US)$ Officer SCIASCIA THOMAS intends to sell 53,368 shares of its common stock on May 29, with a total market value of approximately $136.62K.

moomoo NewsMay 29 16:41 ET

Trevi Therapeutics(TRVI.US) Officer Sells US$71,575.78 in Common Stock

$Trevi Therapeutics(TRVI.US)$ Officer GOOD JENNIFER L sold 25,037 shares of common stock on May 20, 2024 at an average price of $2.8588 for a total value of $71,575.78.Source: Announcement What is sta

moomoo NewsMay 22 17:14 ET